title: Conservative management of stage I endometrial carcinoma after surgical staging.
abstract: OBJECTIVE
  The aim of this study was to determine the outcomes of Stage I endometrial carcinoma patients who are managed without adjuvant radiation after comprehensive surgical staging.
  
  
  METHODS
  A computerized hospital database identified women diagnosed with adenocarcinoma of the endometrium from 1993 to 1998. A chart review identified 864 women as having primary surgery for adenocarcinoma of the endometrium. A total of 670 of 864 patients (78%) underwent comprehensive surgical staging with total hysterectomy, bilateral salpingo-oophorectomy, pelvic/para-aortic lymphadenectomy, and peritoneal cytology. After 57 patients with high-risk histologic subtypes were excluded, 613 patients remained for analysis.
  
  
  RESULTS
  A total of 321 of 325 Stage IB patients (99%) did not receive adjuvant radiation. Fifteen of 321 patients (5%) recurred; 9 recurred in the pelvis or vagina. All 9 local recurrences were salvaged with whole pelvic radiation (XRT) and brachytherapy (BT). Seventy-seven patients were diagnosed with Stage IC disease; 53 (69%) received no adjuvant therapy. Four patients (8%) recurred, of which 2 recurred in the vagina. Three of 4 patients (75%) were salvaged, 2 with XRT/BT and 1 with surgery and chemotherapy. For all Stage I patients, the 5-year disease-free survival was 93% and the 5-year overall survival was 98%.
  
  
  CONCLUSIONS
  Surgically staged patients with endometrial carcinoma confined to the uterine corpus have a small risk of recurrence and the majority of these recurrences can be salvaged with radiation therapy. Conservative management of Stage I endometrial carcinoma patients is an effective treatment strategy.
authors.affiliation: Division of Gynecologic Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA. jmstraughn@yahoo.com
authors.forename: J Michael
authors.initials: JM
authors.lastname: Straughn
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
authors.forename: F Joseph
authors.initials: FJ
authors.lastname: Kelly
authors.forename: Charles A
authors.initials: CA
authors.lastname: Leath
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Kleinberg
authors.forename: Johnny
authors.initials: J
authors.lastname: Hyde
authors.forename: T Michael
authors.initials: TM
authors.lastname: Numnum
authors.forename: Yuting
authors.initials: Y
authors.lastname: Zhang
authors.forename: Seng-Jaw
authors.initials: SJ
authors.lastname: Soong
authors.forename: J Maxwell
authors.initials: JM
authors.lastname: Austin
authors.forename: Edward E
authors.initials: EE
authors.lastname: Partridge
authors.forename: Larry C
authors.initials: LC
authors.lastname: Kilgore
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome